Trials / Available
AvailableNCT05572996
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Ferrer Internacional S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inhaled Treprostinil |
Timeline
- First posted
- 2022-10-10
- Last updated
- 2022-10-10
Source: ClinicalTrials.gov record NCT05572996. Inclusion in this directory is not an endorsement.